PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PR Newswire•21/09/2026•16:30 ET
0
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy PR Newswire
WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.
Get started
Create a free account to read the full story and Whiz Insights.